23andMe (ME)
(Delayed Data from NSDQ)
$0.45 USD
-0.01 (-2.68%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $0.45 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ME 0.45 -0.01(-2.68%)
Will ME be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ME based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for ME
The 3 Best Personalized Nutrition Stocks to Buy Now
23andMe And Nightingale Health Announce Strategic Collaboration To Pilot Blood Biomarker Panel
23andMe, Nightingale Health collaborate to pilot blood biomarker panel
SA Asks: What is the No. 1 cybersecurity threat facing companies today?
Looking Into 23andMe Holding's Recent Short Interest